Biotech · Private company · Ellsworth, ME, US
Revidia Therapeutics, Inc
Track this companyFree. Adds Revidia Therapeutics, Inc to your Dealase workspace and tells you when its record changes.
Clinical trials0None registered
Pipeline programs0None found yet
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
NIH awards1
- IND-enabling safety and toxicity testing of a subcutaneous formulation of the PTP1B inhibitor MSI-1436, a novel strategy for treating fatal cardiomyopathy in Duchenne muscular dystrophy patientsFiscal year 2024 · $1.4MNIH RePORTER 1R44HL174171-01 · fetched Nov 12, 2026